J&J | JNJ - Selling And Administration Expenses


J&J reported $6.25B in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Abbott USD 4.27B 669M Sep/2026
Amgen USD 1.68B 40M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Baxter International USD 730M 5M Sep/2026
Bayer EUR 4.02B 53M Sep/2026
Becton, Dickinson and Co. USD 1.26B 1000K Sep/2026
Biogen USD 752M 42.3M Sep/2026
Boston Scientific USD 1.68B 120M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
CONMED USD 136.42M 9.14M Sep/2026
Cooper Companies USD 401.3M 274.9M Jun/2026
Dexcom USD 358.7M 9M Jun/2026
Edwards Lifesciences USD 560.9M 300K Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Globus Medical USD 288.47M 1.65M Sep/2026
Insulet USD 350.7M 5.9M Sep/2026
Integra LifeSciences USD 161.02M 5.2M Sep/2026
Intuitive Surgical USD 1.08B 465.5M Sep/2026
J&J USD 6.25B 168M Sep/2026
Medtronic 3.2B 141M Jun/2026
Merck USD 2.86B 25M Sep/2026
Merit Medical Systems USD 129.23M 18.76M Jun/2026
Novartis USD 3.08B 163M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026
Stryker USD 2.12B 32M Jun/2026
Tandem Diabetes Care USD 113.94M 2.3M Sep/2026
Teva Pharmaceutical Industries USD 1.01B 27M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026
Zimmer Biomet Holdings USD 855M 56.6M Sep/2026
Zoetis USD 582M 10M Sep/2026